TNF-α Blockade Mitigates Immune Checkpoint-Related Nephritis in a Humanized Mouse Model ⁦@JCI_insight⁩ @VictorCuenca3 @MayoClinicNeph @onconephsociety #onconephrology First Immunocompetent chimeric 🐁 Model of ICI-AIN ! pubmed.ncbi.nlm.nih.gov/4178…

Starting off the “Mayo Clinic Day” at the XV Dominican Congress of Nephrology in collaboration with @MayoClinicNeph and Dominican Society of Nephrology. Starting off the day with Dr. @AnvariEvamaria and Update in Podocytopathies #Neph #SODONEF @SLANH_

Recommendations for the Management of Anemia in Patients with Cancer and Chronic Kidney Disease: A Position Statement from the American Society of Onco-Nephrology (ASON) - Kidney International kidney-international.org/art… @onconephsociety

Our Mini Review is now featured in the October 2026 issue of the American Journal of Kidney Diseases (AJKD)! @AJKDonline “Steroid Minimization in Kidney Transplantation: Rationale, Implementation, and Future Directions” Read the article: doi.org/10.1053/j.ajkd.2026.… In this review, we discuss the evolving role of steroid minimization after kidney transplantation, including the rationale, implementation strategies, clinical tradeoffs, and opportunities for more individualized immunosuppression. It was a privilege to collaborate with Dr. David A. Axelrod, Dr, Yasar Caliskan, and Dr. Krista L. Lentine on this work. @KristaLentine 🙏🏻😊 Many thanks to the American Journal of Kidney Diseases (AJKD) and National Kidney Foundation for highlighting our article in the October issue. 📖 Read the article: doi.org/10.1053/j.ajkd.2026.…

Take a look at this very useful and practical editorial by @HerrmannMd @MBarbarini Drug-Induced Thrombotic Microangiopathy in Cancer ovid.com/10.34067/KID.000000…

Yi Lin, MD, PhD, describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma. Learn more about the science behind the study in the editorial “Anito-cel for Multiple Myeloma”: nej.md/4hF5Gxj

Honored to have been invited as a speaker at @OncnephBoston26 at #harvard. A dream come true. 🙏🙏🙏🙏 for inviting me @ShrutiGkidney @rc_oncneph

Thanks you @marclebiodoura1 #SBN Brazilian Society of Nephrology #onconephrology @MayoClinicNeph

Excellent lecture by @HerrmannMd - use of biomarkers to assess nephrotoxicity associated with cancer immunotherapy. Brazilian Congress of Nephrology 2026. @MayoClinicNeph

MGRS is a moving target. The updated IKMG/RPS framework expands the spectrum of lesions and also removes some entities previously considered MGRS. The key message: finding a monotypic/monoclonal deposit does not automatically mean MGRS. Dr Samir Nasr @MayoClinic @rc_oncneph

🥊 The most awaited session! THE WAR AGAINST LIGHT CHAINS: A Case Debate Two giants. One controversial question. Dr Nelson Leung — PLEX Vs Dr Kenar Jhaveri (@kdjhaveri)— NO PLEX Case presented by Raad Chowdhury @rc_oncneph & Sujal Shah @sujal

If you work in onconephrology, Dr Nelson Leung is one of those names you keep coming back to. Mayo nephrologist + hematologist, and founder/president of the International Kidney & Monoclonal Gammopathy Research Group. @rc_oncneph @MayoClinicNeph

Congrats @ShrutiGkidney & @rc_oncneph for an engaging symposium! There is still so much to understand about complement in cancer, which makes the road ahead all the more exciting. Thank you for having me! Fantastic talks by @aishaikh @HerrmannMd @PepaSolerR @onconeph

A useful OncoNephrology session by Aisha Shaikh @aishaikh on a deceptively simple question: What’s the GFR? Kidney function matters throughout cancer care, from trial eligibility and drug dosing to recognising nephrotoxicity. @rc_oncneph @ShrutiGkidney

SGLT2is: Are they a Miracle for Cancer-Associated Nephrotoxicity Too? María José Soler @PepaSolerR SGLT2i already have a strong cardio-renal story The ❓ in OncoNeph is whether these benefits extend to patients receiving potentially nephrotoxic cancer therapies @rc_oncneph

Excellent opening lecture at the Brazilian Congress of Nephrology, the largest nephrology event in Latin America. @AJBentall @MayoClinicNeph #KidneyTransplant #Nephrology

How do we dose chemotherapy in patients with CKD? 🎙️@onconeph The uncomfortable answer is that for many drugs, the evidence is limited. CKD patients are often excluded from trials, leaving us to balance efficacy, toxicity & imperfect estimates of kidney function @rc_oncneph

@HerrmannMd is fantastic!! And on our speed dial for oncology teams at @MayoCancerCare @AMansfieldMD @KLeventakos @deeptibehl1 @OncoThor

Thanks Dr @rc_oncneph and @ShrutiGkidney for the invitation! Outstanding meeting with great discussions ! @MayoClinicNeph @OncnephBoston26 @onconephsociety

Murine Models & Immune Therapy: What Can Mice Teach Us About AIN ? 🎙️ @HerrmannMd How do we understand ICI-AIN when kidney biopsies give us only a snapshot? Murine models let us track immune cells over time, dissect mechanisms and test potential therapies @rc_oncneph

Listening to @HerrmannMd speaking about preclinical models of ICI toxicity in the kidney here at the @OncnephBoston26 @ShrutiPatelMD @rc_oncneph @AbdullahJalalMD @DanaFarberNews @MayoClinic